COYA News and Press, Coya Therapeutics Inc.

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT ─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders Coya...

2026-01-30 08:47:22 ET More on Coya Therapeutics Seeking Alpha’s Quant Rating on Coya Therapeutics Historical earnings data for Coya Therapeutics Financial information for Coya Therapeutics Read the full article on Seeking Alpha For further det...

- Dr. Reddy’s Laboratories, Inc., a subsidiary of Coya’s current strategic collaborator, makes a $10 million investment - Greenlight Capital, Coya’s largest institutional shareholder, is the only other investor participating in the offering Coya Therapeuti...

Robust target engagement was observed, with statistically significant increases in regulatory T-cell (Treg) suppressive function and Treg numbers beginning as early as two weeks post-dosing and sustained through the 22-week treatment period. Cognitive measures remained stable, with no evidenc...

The CTA No Objection Letter from Health Canada allows for initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers. The ALSTARS Trial is a phase 2, placebo-controlled study that includes clinical sites in the United States and Canada to evaluate the efficacy and safety of...

2025-12-14 23:48:00 ET This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn’s Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn’s regulatory 13F Form filed on 11/14/2025. Please visit our ...

The ALSTARS Trial is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) being conducted at clinical sites in the United States and Canada Dosing of ALS patients has ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company’s manageme...

2025-11-12 09:30:49 ET More on Coya Therapeutics Coya Therapeutics slides after pricing $20M stock offering Coya Therapeutics jumps as Greenlight discusses in Q3 letter Seeking Alpha’s Quant Rating on Coya Therapeutics Historical earnings data for Coya...

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for t...